


**Cancel Claims 31 – 45.**

**Please add Claims 46 – 54 as set forth in the attached Complete Listing of Pending Claims.**

COMPLETE LISTING OF PENDING CLAIMS.

Claims 1 –45 (Cancelled)

46. (new) A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, said condition being selected from the group consisting of breast cancer, colon cancer and leukemia, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where **X** is S or O;

**R**<sub>1</sub> is, independently, H or lower alkyl of 1 to 6 carbons;

**R**<sub>2</sub> and **R**<sub>3</sub> are, independently, H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

**m** is an integer 0 to 3;

**o** is an integer 0 to 4;


**n** is 0-5;

**Y** is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl; and

**B** is COOH, a pharmaceutically acceptable salt thereof, CONR<sub>6</sub>R<sub>7</sub> or COOR<sub>8</sub> where R<sub>6</sub> and R<sub>7</sub>, independently, are hydrogen or an alkyl group of 1 to 6 carbons and R<sub>8</sub> is alkyl of 1 to 6 carbons,


said composition being adapted to be used in combination with interferon.

47. (new) A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, said condition being selected from the group consisting of breast cancer and leukemia, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where **R**<sub>1</sub> is H or methyl, **R**<sub>3</sub> is H or methyl, and **R\***<sub>8</sub> is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, said composition being adapted to be used in combination with interferon.


48. (new) A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, said condition being selected from the group consisting of breast cancer and leukemia, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where **R**<sub>8</sub> is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with interferon.

49. (new) A method of treating a malignant disease or condition in a mammal in need of such treatment, said condition being selected from the group consisting of breast cancer and leukemia, the method comprising the steps of:

administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where X is S or O;

R<sub>1</sub> is, independently, H or lower alkyl of 1 to 6 carbons;

R<sub>2</sub> and R<sub>3</sub> are, independently, H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;


n is 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl;

B is COOH, a pharmaceutically acceptable salt thereof, CONR<sub>6</sub>R<sub>7</sub> or COOR<sub>8</sub> where R<sub>6</sub> and R<sub>7</sub>, independently, are hydrogen or an alkyl group of 1 to 6 carbons and R<sub>8</sub> is alkyl of 1 to 6 carbons, and co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with interferon.

**50.** (new) A method in accordance with Claim 49 where the chemotherapeutic agent is human recombinant interferon  $\alpha$ , human recombinant interferon  $\beta$ , or human recombinant interferon  $\gamma$ .


**51.** (new) A method of treating a malignant disease or condition in a mammal in need of such treatment, said condition being selected from the group consisting of breast cancer and leukemia, the method comprising the steps of:  
administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where R<sub>1</sub> is H or methyl, R<sub>3</sub> is H or methyl, and R<sup>\*</sup><sub>8</sub> is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, and co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with interferon.

**52.** (new) A method in accordance with Claim 51 where the chemotherapeutic agent is human recombinant interferon  $\alpha$ , human recombinant interferon  $\beta$ , or human recombinant interferon  $\gamma$ .

**53.** (new) A method of treating a malignant disease or condition in a mammal in need of such treatment, said condition being selected from the group consisting of breast cancer and leukemia, the method comprising the steps of:  
administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where R<sub>8</sub> is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, and

co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with interferon.

**54. (new)** A method in accordance with Claim 44 where the chemotherapeutic agent is human recombinant interferon  $\alpha$ , human recombinant interferon  $\beta$ , or human recombinant interferon  $\gamma$ .